Back to Peptides
Skin & JointLow Risk

Rigin

Also known as: Palmitoyl Tetrapeptide-7, Pal-GQPR, Matrixyl 3000 component

Half-life:
N/A (topical)

Administration Routes

topical
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

The anti-inflammatory partner to Matrixyl. Together they form Matrixyl 3000. Reduces skin inflammation, suppresses IL-6, supports matrix integrity, and enhances collagen production.

Primary Research Areas

  • anti-inflammatory (skin)
  • skin tightening
  • extracellular matrix support
  • wrinkle reduction

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Cosmetic peptide (palmitoyl tetrapeptide-7). Anti-inflammatory cosmetic ingredient. Not regulated as a drug by FDA. No NDA or IND. Cosmetic use only in skincare formulations.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Rigin